Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer will gain access to King's specialized portfolio of medications for acute, severe pain and to Remoxy, which could catapult the Big Pharma into the controversial but promising field of tamper-resistant opioid medications.

You may also be interested in...



No Near-Term Separations For Pfizer, But Business Model Will “Evolve”

Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.

No Near-Term Separations For Pfizer, But Business Model Will “Evolve”

Beyond the sale of its nutritionals business and spin-out of animal health into Zoetis, no additional separations are planned for Pfizer in the near-term. But CEO Ian Read discussed how he sees the company’s Established Products and Emerging Markets businesses evolving over the long-term, including the potential for an eventual breakout, during a year-end financial call Jan. 29.

With Strong Q3 Financials, Pfizer Says It's Ready For Generic Competition To Lipitor

The world's largest pharma highlights sales growth of Prevnar 13, Enbrel and Lyrica, emerging markets growth, and a developing plan to sell off animal health and nutritional units.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel